BriaCell Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $40.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar’s rating is based on the promising clinical data from BriaCell Therapeutics’ Phase 3 Bria-ABC study, which indicates that their treatment, Bria-IMT, combined with checkpoint inhibitors, shows a significant improvement in progression-free survival (PFS) for patients with metastatic breast cancer who are DTH positive. The study’s results highlighted a statistically significant PFS benefit for DTH+ patients across all treatment arms, suggesting a potential advantage over the general patient population.
Additionally, the safety and tolerability profile of Bria-IMT remains favorable, with no serious adverse effects such as interstitial lung disease or CNS complications reported. The ongoing trial aims to conclude by the end of 2025, with a final analysis expected in 2026. The inclusion of various metastatic breast cancer subtypes and heavily pretreated patients further supports the robustness of the study, enhancing the potential for Bria-IMT to address unmet needs in this patient population.